OSR Holdings, Inc.
$0.6
▼
-6.29%
2026-04-21 08:41:01
www.osr-holdings.com
NCM: OSRH
Explore OSR Holdings, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$19.87 M
Current Price
$0.6
52W High / Low
$1.79 / $0.38
Stock P/E
—
Book Value
$3.46
Dividend Yield
—
ROCE
79.82%
ROE
-20.03%
Face Value
—
EPS
$-0.92
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
0.59
Debt / Equity
3.47
Current Ratio
0.16
Quick Ratio
0.15
Forward P/E
—
Price / Sales
6.1
Enterprise Value
$69.83 M
EV / EBITDA
-7.73
EV / Revenue
24.03
Rating
Hold
Target Price
$10
EPS Forecast (FY)
—
Pros
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
Cons
- Return on equity is on the weaker side.
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Zymeworks Inc. | $27.85 | — | $1.98 B | — | -30.42% | -26.72% | $28.49 / $10.86 | $3.6 |
| 2. | Jade Biosciences, Inc. | $23.5 | — | $1.13 B | 0% | -34.07% | -89.19% | $100.1 / $6.57 | $6.74 |
| 3. | Aura Biosciences, Inc. | $7.05 | — | $467.66 M | — | -74.67% | -73.52% | $7.48 / $4.34 | $2.15 |
| 4. | Pyxis Oncology, Inc. | $1.7 | — | $104.3 M | — | -119.93% | -91.44% | $5.55 / $0.89 | $0.85 |
| 5. | Sarepta Therapeutics, Inc. | $21.42 | — | $2.24 B | — | -29.18% | -53.47% | $64.8 / $10.42 | $10.87 |
| 6. | Alaunos Therapeutics, Inc. | $2.84 | — | $6.71 M | — | -233.25% | -1.98% | $6.2 / $1.67 | $1.27 |
| 7. | Aardvark Therapeutics, Inc. | $5.65 | — | $114.1 M | — | -58.82% | -64.44% | $17.94 / $3.35 | $4.89 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.38 M | 0.63 M | 1.14 M | 0.76 M | -2.62 M | — |
| Operating Profit | -6.39 M | -3.8 M | -5.23 M | -2.92 M | 6.55 M | — |
| Net Profit | -4.82 M | -2.13 M | 0.33 M | -11.39 M | 6.58 M | — |
| EPS in Rs | -0.15 | -0.06 | 0.01 | -0.34 | 0.2 | -1.56 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 2.91 M | 3.53 M | 0 M | 0 M |
| Operating Profit | -18.34 M | -11.69 M | -1.83 M | -0.62 M |
| Net Profit | -18.01 M | -10.33 M | 0.4 M | 1.06 M |
| EPS in Rs | -0.54 | -0.31 | 0.01 | 0.03 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 171.24 M | 175.24 M | 36.63 M | 120.76 M |
| Total Liabilities | 44.2 M | 32.03 M | 4.11 M | 21.66 M |
| Equity | 77.64 M | 143.21 M | 32.52 M | 99.1 M |
| Current Assets | 2.82 M | 2.33 M | 0.02 M | 4.42 M |
| Current Liabilities | 17.17 M | 3.46 M | 2.04 M | 5.86 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -4.33 M | -1.85 M | -0.82 M | -0.52 M |
| Investing CF | -2.64 M | 0.5 M | -33.83 M | -1.71 M |
| Financing CF | 8.37 M | 1.18 M | 34.54 M | 4.72 M |
| Free CF | -4.5 M | -1.85 M | -0.82 M | -0.59 M |
| Capex | -0.18 M | — | -0.02 M | -0.08 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | -17.69% | — | — | — |
| Earnings Growth % | -74.37% | -2658.05% | -62.09% | — |
| Profit Margin % | -619.82% | -292.58% | — | — |
| Operating Margin % | -631.01% | -331.2% | — | — |
| Gross Margin % | 20.4% | 22.98% | — | — |
| EBITDA Margin % | -656.48% | -60.9% | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.